除了傳統的化療藥物外,還有多種類型的抗腫瘤藥物,它們通過不同的機制來抑制癌細胞的生長和擴散。以下是一些常見的類別及其代表藥物:
靶向治療藥物:這類藥物能夠識別并結合到特定的分子或受體上,從而阻止癌細胞分裂和擴散,減少對正常細胞的影響。代表性藥物包括:
免疫治療藥物:通過激活患者自身的免疫系統來識別并攻擊腫瘤細胞。主要類別有單克隆抗體和檢查點抑制劑,如:
血管生成抑制劑:阻止為腫瘤提供營養的血管生長,從而限制癌細胞的生長。代表性藥物有:
DNA修復抑制劑:干擾癌細胞修復其基因組的能力,導致癌細胞死亡。如:
這些藥物各自通過不同的機制對抗腫瘤,適用于不同類型的癌癥治療。臨床應用中需根據患者具體情況選擇合適的治療方案,并在醫生指導下使用。
| 中文名稱 | 英文名稱 | CAS號 | 化學式 |
|---|---|---|---|
| 順鉑 | cisplatine | 15663-27-1 | Cl2H6N2Pt |
| 長春質堿 | Catharanthine | 2468-21-5 | C21H24N2O2 |
| 西地尼布 | cediranib | 288383-20-0 | C25H27FN4O3 |
| 脫水長春堿 | anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| 脫水長春堿 | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| 米托坦 | 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane | 53-19-0 | C14H10Cl4 |
| 硼替佐米 | velcade | 179324-69-7 | C19H25BN4O4 |
| 甲磺酸艾日布林 | eribulin mesylate | 441045-17-6 | CH4O3S*C40H59NO11 |
| 瑞格非尼 | 4-[4({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | 1019206-88-2 | C21H15ClF4N4O3*H2O |
| 法倔唑 | fadrozole | 102676-47-1 | C14H13N3 |
| 氯尼達明 | lonidamine | 50264-69-2 | C15H10Cl2N2O2 |
| 比生群 | bisantrene | 78186-34-2 | C22H22N8 |
| 來那度胺 | Lenalidomide | 191732-72-6 | C13H13N3O3 |
| 奧沙利鉑 | oxaliplatin | 61825-94-3 | C8H14N2O4Pt |
| 卡鉑 | carboplatinum | 41575-94-4 | C6H12N2O4Pt |
| 丙亞胺 | razoxane | 21416-67-1 | C11H16N4O4 |
| [SP-4-2-(1S-反式)]-(1,2-環己烷二胺)[乙二酸]鉑 | oxaliplatin | 141610-50-6 | C8H14N2O4Pt |
| 4-(4-甲基哌嗪甲基)苯甲酰氯 | 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride | 148077-69-4 | C13H17ClN2O |
| —— | Zeniplatin | 111490-36-9 | C11H20N2O6Pt |
| —— | 150399-23-8 | C20H21N5NaO6 | |
| —— | Dimethotrexate | 133073-73-1 | C40H44N16O10 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | 3',4'-Anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | GD-Tex | 156436-89-4 | C52H74GdN5O15 |
| —— | Bisantrene | 71439-68-4 | C22H22N8 |
| —— | catharanthine | 2468-21-5 | C21H24N2O2 |
| —— | 3,4-didehydro-ibogamine-18-carboxylic acid methyl ester | 2468-21-5 | C21H24N2O2 |
| —— | [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II) | 141610-50-6 | C8H16N2O4Pt |
| —— | Combretastatin A4 disodium phosphate | 168555-66-6 | C18H21NaO8P |
| —— | N-[(Z)-[10-[(Z)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine | 78186-34-2 | C22H22N8 |
| —— | cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) | 41575-94-4 | C6H12N2O4Pt |
| —— | bropirimine | 56741-95-8 | C10H8BrN3O |
| —— | disodium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate | 150399-23-8 | C20H19N5Na2O6 |
| —— | cisplatin | 15663-27-1 | Cl2H4N2Pt |
| —— | anhydrovinblastine | 38390-45-3 | C46H56N4O8 |
| —— | (+)-anhydrovinblastine | 38390-45-3 | C46H56N4O8 |